Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AZN save search
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
Published: 2023-11-01 (Crawled : 07:00) - globenewswire.com
CLLS | $2.47 0.4% 12K
|
Health Technology
|
| O: 179.38%
H: 10.33%
C: -2.58%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.03%
H: 1.17%
C: 0.84%
collaboration
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2024-02-05 (Crawled : 12:30) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.17%
H: 0.09%
C: -2.76%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 33.84%
H: 1.01%
C: -15.3%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.76%
H: 0.77%
C: 0.0%
reqorsa first lung cancer treat cell expansion therapy study
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.49%
H: 1.06%
C: -2.49%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 16.79%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
Published: 2021-07-08 (Crawled : 14:15) - biospace.com/
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: 14.31%
H: 0.24%
C: -4.53%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.52%
H: 0.37%
C: -0.32%
license
NeoGenomics Appoints Lynn Tetrault Interim CEO
Published: 2022-05-16 (Crawled : 12:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.73%
H: 0.86%
C: -1.11%
NEO | $13.54 -1.67% -1.7% 770K
|
Health Services
|
| O: 13.56%
H: 1.47%
C: -6.7%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.52%
H: 0.0%
C: 0.0%
ceo
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Published: 2022-11-10 (Crawled : 00:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 6.22%
H: 3.13%
C: -0.56%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 0.17%
H: 6.48%
C: -1.81%
ATXI | $0.1295 -3.79% -3.94% 320K
|
Health Technology
|
| O: -10.64%
H: 30.29%
C: 25.6%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 7.08%
H: 0.84%
C: -0.43%
therapeutics financial results
Diabetes Drugs Global Market Report 2022: Featuring AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Pfizer & More
Published: 2023-03-22 (Crawled : 00:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.11%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 5.54%
H: 0.96%
C: 0.96%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.81%
H: 0.51%
C: 0.51%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.08%
H: 0.34%
C: -0.03%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.69%
H: 0.11%
C: -0.76%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.02%
H: 1.34%
C: 0.53%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 6.53%
H: 0.56%
C: -0.54%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.56%
H: 0.34%
C: -0.52%
report global diabetes market
Clostridium Diagnostics Market to grow at a CAGR of 13.69% from 2022 to 2027, Driven by the growing prevalence of CDI - Technavio
Published: 2023-03-27 (Crawled : 11:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.55%
H: 1.46%
C: -0.08%
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 0.99%
H: 0.78%
C: -0.37%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 6.51%
H: 1.75%
C: 1.4%
TRIB | $1.81 -3.72% -3.87% 5.7K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.32%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.46%
H: 0.53%
C: -0.25%
growing diagnostics market
HUTCHMED Reports 2021 Interim Results and Provides Business Updates
Published: 2021-07-28 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.09%
H: 2.07%
C: 1.29%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 6.45%
H: 7.99%
C: 7.76%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.23%
H: 13.33%
C: 12.51%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.75%
H: 0.7%
C: -0.39%
results
Akoya Biosciences to Host Inaugural Spatial Day on December 15, 2021
Published: 2021-11-22 (Crawled : 13:30) - globenewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.53%
H: 0.0%
C: -0.1%
AKYA | $3.81 -1.04% -1.05% 170K
|
Professional, Scientific, and T...
|
| O: 6.15%
H: 2.32%
C: 1.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.17%
H: 0.0%
C: 0.0%
bioscience
Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
Published: 2021-11-29 (Crawled : 17:00) - globenewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.57%
H: 0.0%
C: 0.0%
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 5.5%
H: 0.0%
C: -11.8%
financial results bioscience results
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
Published: 2022-08-01 (Crawled : 23:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.39%
H: 0.0%
C: -0.9%
AVTX | $11.71 -2.5% -2.56% 68K
|
Manufacturing
|
| O: 4.72%
H: 10.08%
C: -4.51%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.44%
H: 0.53%
C: -1.31%
il-18 therapeutics
Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 5.68%
H: 0.77%
C: 0.77%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.41%
H: 0.0%
C: -2.45%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.08%
H: 3.47%
C: -0.25%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 4.04%
H: 1.57%
C: -3.02%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.5%
H: 0.07%
C: -0.81%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
PBYI | $5.01 0.4% 0.4% 290K
|
Health Technology
|
| O: -0.1%
H: 2.31%
C: -1.26%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.82%
H: 0.12%
C: -1.64%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.44%
H: 0.2%
C: -0.55%
drug breast expected cancer pipeline therapeutics growth market
Topical Corticosteroids Market to Grow by USD 1.08 billion between 2022 to 2027, globally at 4% CAGR - Technavio
Published: 2024-01-30 (Crawled : 23:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 4.34%
H: 0.0%
C: 0.0%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 5.68%
H: 0.77%
C: 0.77%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.41%
H: 0.0%
C: -2.45%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.0%
H: 1.38%
C: 0.26%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.08%
H: 3.47%
C: -0.25%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 4.04%
H: 1.57%
C: -3.02%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.5%
H: 0.07%
C: -0.81%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.82%
H: 0.12%
C: -1.64%
market
Blueprint Medicines Reports First Quarter 2022 Results
Published: 2022-05-03 (Crawled : 12:00) - biospace.com/
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 3.73%
H: 5.92%
C: 3.09%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.48%
H: 1.18%
C: 1.02%
results
Idiopathic Pulmonary Fibrosis Market to Reach $6.16 Bn, Globally, by 2030 at 7.0% CAGR: Allied Market Research
Published: 2022-02-07 (Crawled : 13:30) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.69%
H: 0.5%
C: -1.76%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 3.7%
H: 1.64%
C: 1.24%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 2.54%
H: 1.58%
C: 0.1%
FGEN | $1.15 -1.71% -1.74% 1.3M
|
Health Technology
|
| O: -1.09%
H: 9.3%
C: 8.82%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 2.54%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.14%
H: 1.01%
C: 0.87%
fibrosis research
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 3.49%
H: 0.9%
C: 0.9%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.49%
H: 0.03%
C: -0.61%
phase 2 europe als
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.47%
H: 1.16%
C: -1.27%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 3.34%
H: 0.27%
C: -0.62%
children approved treatment for
Psoriasis Treatment Market Players Observe Rising Trend of Personalized Medicines, According to TMR Report
Published: 2022-06-24 (Crawled : 12:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.64%
H: 4.18%
C: 1.33%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 6.71%
H: 0.0%
C: -0.1%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 2.96%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.94%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 3.32%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 4.41%
H: 0.0%
C: 0.0%
treatment report psoriasis market
AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers
Published: 2022-02-22 (Crawled : 21:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 3.24%
H: 0.18%
C: -1.6%
partnership program respiratory one
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.